Literature DB >> 7622248

Comparison of spleen cell proliferation in response to Brucella abortus 2308 lipopolysaccharide or proteins in mice vaccinated with strain 19 or RB51.

M G Stevens1, S C Olsen, G W Pugh.   

Abstract

Mice vaccinated with Brucella abortus 19 (S19) or RB51 (SRB51) had spleen cells which proliferated in response to proteins of 32, 27, 18, and < 18 kDa but not in response to proteins of 106, 80, and 49 kDa from B. abortus 2308 (S2308) following vaccination and challenge infection with S2308. Spleen cells from mice vaccinated with S19 but not with SRB51 had increased proliferation in response to S2308 lipopolysaccharide (LPS) following challenge infection with S2308. We previously reported that mice vaccinated with S19 or SRB51, which were analyzed in the current study, have increased resistance to infection with S2308 and that only mice vaccinated with S19 produce antibody to S2308 LPS (M. Stevens, S. Olsen, G. Pugh, Jr., and D. Brees, Infect. Immun. 63:264-270, 1995). The results from our current and previous studies support the contention that vaccination of mice with S19 or SRB51 induces protection from infection with S2308 by cell-mediated immune responses to the same immunodominant (32, 27, 18, and < 18 kDa) protein antigens of S2308. In addition, the absence of S2308 LPS-responsive spleen cells and antibody to S2308 LPS in mice vaccinated with SRB51 suggests that immune responses to LPS have no role in SRB51-induced protective immunity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622248      PMCID: PMC173437          DOI: 10.1128/iai.63.8.3199-3205.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

Review 1.  Immunomodulation by bacterial endotoxin.

Authors:  R Burrell
Journal:  Crit Rev Microbiol       Date:  1990       Impact factor: 7.624

2.  Comparative protection of mice against virulent and attenuated strains of Brucella abortus by passive transfer of immune T cells or serum.

Authors:  L N Araya; A J Winter
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

3.  Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus.

Authors:  L N Araya; P H Elzer; G E Rowe; F M Enright; A J Winter
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

4.  Identification of seven surface-exposed Brucella outer membrane proteins by use of monoclonal antibodies: immunogold labeling for electron microscopy and enzyme-linked immunosorbent assay.

Authors:  A Cloeckaert; P de Wergifosse; G Dubray; J N Limet
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

5.  Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308.

Authors:  M G Stevens; S C Olsen; G W Pugh; M V Palmer
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Biological properties of RB51; a stable rough strain of Brucella abortus.

Authors:  G G Schurig; R M Roop; T Bagchi; S Boyle; D Buhrman; N Sriranganathan
Journal:  Vet Microbiol       Date:  1991-07       Impact factor: 3.293

7.  Protection against Brucella melitensis or Brucella abortus in mice with immunoglobulin G (IgG), IgA, and IgM monoclonal antibodies specific for a common epitope shared by the Brucella A and M smooth lipopolysaccharides.

Authors:  A Cloeckaert; I Jacques; P de Wergifosse; G Dubray; J N Limet
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

8.  Lipopolysaccharide from Brucella abortus behaves as a T-cell-independent type 1 carrier in murine antigen-specific antibody responses.

Authors:  M Betts; P Beining; M Brunswick; J Inman; R D Angus; T Hoffman; B Golding
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Immune responses and protection against infection and abortion in cattle experimentally vaccinated with mutant strains of Brucella abortus.

Authors:  N F Cheville; M G Stevens; A E Jensen; F M Tatum; S M Halling
Journal:  Am J Vet Res       Date:  1993-10       Impact factor: 1.156

10.  Serologic responses in diagnostic tests for brucellosis in cattle vaccinated with Brucella abortus 19 or RB51.

Authors:  M G Stevens; S G Hennager; S C Olsen; N F Cheville
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

View more
  7 in total

1.  Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection.

Authors:  P Pasquali; R Adone; L C Gasbarre; C Pistoia; F Ciuchini
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

2.  Immune responses and resistance to brucellosis in mice vaccinated orally with Brucella abortus RB51.

Authors:  M G Stevens; S C Olsen; M V Palmer; G W Pugh
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

3.  Brucella abortus RB51 induces protection in mice orally infected with the virulent strain B. abortus 2308.

Authors:  Paolo Pasquali; Adone Rosanna; Claudia Pistoia; Paola Petrucci; Franco Ciuchini
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

4.  Lymphocyte proliferation in response to Brucella abortus RB51 and 2308 proteins in RB51-vaccinated or 2308-infected cattle.

Authors:  M G Stevens; S C Olsen; N F Cheville
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

5.  Antibody responses to Brucella abortus 2308 in cattle vaccinated with B. abortus RB51.

Authors:  M G Stevens; S C Olsen
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

6.  Immunological response to Brucella abortus strain 19 vaccination of cattle in a communal area in South Africa.

Authors:  Gregory J G Simpson; Tanguy Marcotty; Elodie Rouille; Abel Chilundo; Jean-Jacques Letteson; Jacques Godfroid
Journal:  J S Afr Vet Assoc       Date:  2018-03-29       Impact factor: 1.474

7.  Caspase-2 mediated apoptotic and necrotic murine macrophage cell death induced by rough Brucella abortus.

Authors:  Fang Chen; Yongqun He
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.